SG11202105745UA - Crystalline forms of a compound for treating or preventing gout or hyperuricemia - Google Patents
Crystalline forms of a compound for treating or preventing gout or hyperuricemiaInfo
- Publication number
- SG11202105745UA SG11202105745UA SG11202105745UA SG11202105745UA SG11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA SG 11202105745U A SG11202105745U A SG 11202105745UA
- Authority
- SG
- Singapore
- Prior art keywords
- hyperuricemia
- treating
- compound
- crystalline forms
- preventing gout
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018119567 | 2018-12-06 | ||
| PCT/US2019/064784 WO2020118113A1 (en) | 2018-12-06 | 2019-12-05 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105745UA true SG11202105745UA (en) | 2021-06-29 |
Family
ID=70974392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105745UA SG11202105745UA (en) | 2018-12-06 | 2019-12-05 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220024889A1 (ko) |
| EP (1) | EP3890723A4 (ko) |
| JP (1) | JP2022511800A (ko) |
| KR (1) | KR20210100677A (ko) |
| CN (1) | CN113226302B (ko) |
| AU (1) | AU2019394974A1 (ko) |
| BR (1) | BR112021010708A2 (ko) |
| CA (1) | CA3121913A1 (ko) |
| EA (1) | EA202191545A1 (ko) |
| IL (1) | IL283663A (ko) |
| SG (1) | SG11202105745UA (ko) |
| TW (1) | TWI828817B (ko) |
| WO (1) | WO2020118113A1 (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015371308A1 (en) | 2014-12-23 | 2017-08-03 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| JP2019524747A (ja) | 2016-07-18 | 2019-09-05 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| CN113874014A (zh) * | 2019-05-14 | 2021-12-31 | 安索治疗公司 | 用于治疗痛风或高尿酸血症的化合物 |
| EP4164624A1 (en) * | 2020-06-10 | 2023-04-19 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing chronic kidney disease |
| WO2023098872A1 (en) * | 2021-12-02 | 2023-06-08 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5844376B2 (ja) * | 2010-10-06 | 2016-01-13 | ジェイファーマ株式会社 | 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物 |
| US9060987B2 (en) * | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| CN104736178A (zh) * | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
| CN104262305B (zh) * | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN104311516B (zh) * | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| JP2019524747A (ja) * | 2016-07-18 | 2019-09-05 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 |
-
2019
- 2019-12-05 CN CN201980080515.8A patent/CN113226302B/zh active Active
- 2019-12-05 EA EA202191545A patent/EA202191545A1/ru unknown
- 2019-12-05 CA CA3121913A patent/CA3121913A1/en active Pending
- 2019-12-05 AU AU2019394974A patent/AU2019394974A1/en active Pending
- 2019-12-05 US US17/311,249 patent/US20220024889A1/en active Pending
- 2019-12-05 BR BR112021010708-8A patent/BR112021010708A2/pt unknown
- 2019-12-05 SG SG11202105745UA patent/SG11202105745UA/en unknown
- 2019-12-05 EP EP19893127.1A patent/EP3890723A4/en active Pending
- 2019-12-05 WO PCT/US2019/064784 patent/WO2020118113A1/en unknown
- 2019-12-05 KR KR1020217021172A patent/KR20210100677A/ko unknown
- 2019-12-05 JP JP2021531047A patent/JP2022511800A/ja active Pending
- 2019-12-06 TW TW108144814A patent/TWI828817B/zh active
-
2021
- 2021-06-02 IL IL283663A patent/IL283663A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019394974A1 (en) | 2021-07-15 |
| CA3121913A1 (en) | 2020-06-11 |
| IL283663A (en) | 2021-07-29 |
| WO2020118113A1 (en) | 2020-06-11 |
| JP2022511800A (ja) | 2022-02-01 |
| TWI828817B (zh) | 2024-01-11 |
| BR112021010708A2 (pt) | 2021-08-24 |
| EP3890723A4 (en) | 2022-08-03 |
| US20220024889A1 (en) | 2022-01-27 |
| CN113226302B (zh) | 2023-08-18 |
| CN113226302A (zh) | 2021-08-06 |
| EP3890723A1 (en) | 2021-10-13 |
| TW202039453A (zh) | 2020-11-01 |
| EA202191545A1 (ru) | 2021-10-28 |
| KR20210100677A (ko) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283663A (en) | Crystalline forms of a compound for the treatment or prevention of rheumatism or hyperuricemia | |
| IL257960A (en) | A group of substances used to treat or prevent hyperuricemia or gout | |
| IL288034A (en) | A compound for the treatment of gout or hyperuricemia | |
| EP3619208C0 (en) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| PL3826982T3 (pl) | Zastosowanie podstawionych związków tiazolidynowych jako inhibitora nitryfikacji | |
| IL283665A (en) | Methods for treating or preventing rheumatism or hyperuricemia | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| IL278054A (en) | The crystalline forms of a compound | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| SG11202009262VA (en) | Salts of compounds and crystals thereof | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| IL292206A (en) | The salts of a compound and its crystalline forms | |
| GB201915908D0 (en) | Crystalline forms of entrectinib | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| IL284564A (en) | Polymorphic forms of a modified quinoline-type bridged piperidine compound | |
| IL284222A (en) | Macrocrystalline forms of the PAR4 inhibitor | |
| ZA202006134B (en) | Oxazole compound crystal |